1Tanner M, Gancberg D, Di L A, et al. Chromogenic in situ hybridization: a practical alternative for flouresence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer sample[J]. Am J Pathol, 2000, 157(5): 1467-1472. 被引量：1
2Meijers H H, Brekelmans C T, Menke P M, et al. Use of genetic test and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation[J]. J Clin Oncol, 2003, 21: 1675-1681. 被引量：1
3Birner P, Oberhuber G, Stani J, et al. Evaluation of the united states food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer[J]. Clin Cancer Res, 2001, 7(6): 1669-1675. 被引量：1
4Apantaku L M. Breast cancer diagnosis and screening[J]. Am Fam Physician, 2000, 62: 596-602. 被引量：1
5Lipton A, Ali S M, Leitzed K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer[J]. J Clin Oncol, 2002, 20(6): 1467-1472. 被引量：1
6Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J ]. N Engl J Med, 2001, 344(11): 783-7921. 被引量：1
7Miles D W. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting[J]. Breast Cancer Res, 2001, 3(6): 380-3841. 被引量：1
8King M C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention Trial[J]. JAMA, 2001, 286(18): 2551-2556. 被引量：1
9Narod S A, Brunet J S, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case?control study[J]. Lancet, 2000,356:1876-1881. 被引量：1
10Meijers-Heijboer H, Van-Geel B, Van-Putten W L, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation[J]. N Engl J Med, 2001, 345:159-164. 被引量：1
